scispace - formally typeset
M

Mark D. Johnson

Researcher at University of Massachusetts Medical School

Publications -  301
Citations -  18425

Mark D. Johnson is an academic researcher from University of Massachusetts Medical School. The author has contributed to research in topics: Medicine & Gene. The author has an hindex of 60, co-authored 289 publications receiving 16103 citations. Previous affiliations of Mark D. Johnson include National Institutes of Health & Georgetown University Medical Center.

Papers
More filters
Journal ArticleDOI

Comparative analysis of algorithms for identifying amplifications and deletions in array CGH data

TL;DR: 11 different algorithms for analyzing array CGH data are compared, based on diverse techniques such as mixture models, Hidden Markov Models, maximum likelihood, regression, wavelets and genetic algorithms, to reveal general characteristics that are helpful to the biological investigator.
Journal ArticleDOI

Perioperative patient outcomes in the African Surgical Outcomes Study: a 7-day prospective observational cohort study

Bruce M Biccard, +1062 more
- 21 Apr 2018 - 
TL;DR: Despite a low-risk profile and few postoperative complications, patients in Africa were twice as likely to die after surgery when compared with the global average for postoperative deaths, and Initiatives to increase access to surgical treatments in Africa should be coupled with improved surveillance for deteriorating physiology in patients who develop postoperative complication.
Journal ArticleDOI

Inhibition of angiogenesis by tissue inhibitor of metalloproteinase.

TL;DR: Using an in vivo angiogenesis assay, the endothelial cell response to known angiogenic factors, basic fibroblast growth factor and adipocyte conditioned medium, was blocked by an inhibitor of matrix metalloproteinase activity, TIMP‐1.
Journal ArticleDOI

Toxicogenomics-Based Discrimination of Toxic Mechanism in HepG2 Human Hepatoma Cells

TL;DR: The present studies demonstrate a general application of toxicogenomics that distinguishes two mechanistically unrelated classes of toxicants (cytotoxic anti-inflammatory drugs and DNA-damaging agents) based solely upon a cluster-type analysis of genes differentially induced or repressed in cultured cells during exposure to these compounds.
Journal ArticleDOI

Improved diagnosis of Becker muscular dystrophy by dystrophin testing.

TL;DR: Dystrophin analysis is required for accurately distinguishing between Becker dystrophy and clinically similar autosomal recessive myopathies, and the correlation of both the biochemical and clinical data suggests that Duchenne/Becker Dystrophy can be divided into 4 clinically useful categories.